IMMX
NASDAQ HealthcareImmix Biopharma, Inc. - Common Stock
Biotechnology
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
๐ Market Data
| Price | $11.34 |
|---|---|
| Volume | 1,237,511 |
| Market Cap | 807.29M |
| Beta | 0.110 |
| RSI (14-Day) | 73.1 Overbought |
| 200-Day MA | $7.76 |
| 50-Day MA | $9.58 |
| 52-Week High | $12.14 |
| 52-Week Low | $1.94 |
| Forward P/E | -12.55 |
| Price / Book | 3.54 |
๐ฏ Investment Strategy Scores
IMMX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (87/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find IMMX in your text
Paste any article, transcript, or post โ the tool will extract IMMX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.